Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Electrochemotherapy for Breast Cancer-Results From the INSPECT Database

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hereditary breast cancer: clinical, pathological and molecular characteristics

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Fulvestrant is a selective oestrogen receptor (ER) degrader used as monotherapy and combination therapy for ER positive HER2 negative advanced breast cancer (ABC) in postmenopausal women. The drug response predictor (DRP), is a mathematical algorithm based on the expression of multiple genes in the tumour. The fulvestrant DRP algorithm has previously shown effect in BC. In this study, we investigated the DRP's potential in predicting fulvestrant benefit.

METHOD: Among 695 patients with ABC prospectively included in a Danish Breast Cancer Cooperative Group (DBCG) cohort we retrospectively included 226 patients who received fulvestrant as monotherapy. The DRP result was based on mRNA extracted from tumour biopsies and analysed using Affymetrix array. Primary endpoint was time to progression (TTP).

RESULTS: For patients who received fulvestrant in line one to four and were previously unexposed to adjuvant endocrine therapy, we identified a hazard ratio (HR) of 0.44 (90% confidence interval (90% CI) upper limit of 1.08, one sided p = 0.066) for a predicted positive vs negative outcome. A weaker association was seen when including patients exposed to adjuvant endocrine treatment or received fulvestrant in fifth or later lines. Exploratory analyses showed that the DRP was efficient when using recent biopsies for DRP estimate and among recently treated patients.

CONCLUSION: The DRP showed a potential in predicting fulvestrant treatment but was not significant in the overall analysis. Use of older biopsies, long-term endocrine treatment and multiple therapies between biopsy used for analysis and fulvestrant treatment, probably affect the predictive accuracy.

Original languageEnglish
JournalBreast Cancer: Basic and Clinical Research
Publication statusE-pub ahead of print - 2020

    Research areas

  • Advanced breast cancer, Biomarker, Fulvestrant, Messenger RNA

ID: 58227231